As a novel agent, RC48 as monotherapy or adjuvant treatment in clinical practice for the therapy of other cancer in the world, including UC in China and the USA, biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), and HER2+ and HER2-low expressing BC in China (Table 3). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.